Elevation Oncology Inc. (ELEV)
NASDAQ: ELEV
· Real-Time Price · USD
0.38
0.06 (18.79%)
At close: Jun 09, 2025, 3:59 PM
Elevation Oncology Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | 58K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | 5K | 4K | 10K | 10K | 9K | 10K | 10K | 10K | 8K | 5K | 4K | 5K | 3K | 6K | 4K |
Gross Profit | n/a | n/a | -5K | -4K | -10K | 48K | -9K | -10K | -10K | -10K | -8K | -5K | -4K | -5K | -3K | -6K | -4K |
Operating Income | -14.22M | -10.64M | -13.23M | -10.96M | -9.87M | -7.95M | -10.92M | -9.83M | -16.75M | -18.54M | -38.53M | -20.11M | -17.37M | -9.62M | -12.28M | -5.06M | -5.09M |
Interest Income | n/a | n/a | n/a | n/a | n/a | 3.9M | n/a | 234.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -14.21M | -10.43M | -12.87M | -10.45M | -10.7M | -7.89M | -10.63M | -10.11M | -17.05M | -19.02M | -38.84M | -19.93M | -17.27M | -9.62M | -12.27M | -5.06M | -5.09M |
Net Income | -14.21M | -10.44M | -12.88M | -10.46M | -10.71M | -7.9M | -10.64M | -10.11M | -17.06M | -19.04M | -39.14M | -19.74M | -17.18M | -9.62M | -12.27M | -5.06M | -5.09M |
Selling & General & Admin | 3.96M | 4M | 3.84M | 4.41M | 3.85M | 3.25M | 3.5M | 3.81M | 4.35M | 4.04M | 4.19M | 3.81M | 3.79M | 3.38M | 2.98M | 1.15M | 952K |
Research & Development | 6.88M | 6.65M | 9.39M | 6.55M | 6.01M | 4.69M | 7.42M | 6.03M | 7.29M | 14.5M | 34.34M | 16.3M | 13.57M | 6.25M | 9.3M | 3.91M | 4.13M |
Other Expenses | 3.38M | n/a | n/a | n/a | n/a | 56K | 295K | -271K | -309K | -480K | -306K | 187K | 93K | 2K | 10K | n/a | -5K |
Operating Expenses | 14.22M | 10.64M | 13.23M | 10.96M | 9.86M | 7.94M | 10.92M | 9.83M | 11.64M | 18.54M | 38.53M | 20.11M | 17.37M | 9.62M | 12.28M | 5.06M | 5.09M |
Interest Expense | n/a | 575K | n/a | 513K | 115K | 4.17M | n/a | n/a | 309K | 470K | 306K | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | -3.84M | n/a | -4K | 3.84M | -10K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 10.64M | 13.23M | 10.96M | 9.87M | 7.95M | 10.92M | 9.83M | 11.64M | 18.54M | 38.53M | 20.11M | 17.37M | 9.62M | 12.28M | 5.06M | 5.09M |
Income Tax Expense | 6K | 9K | 12K | 11K | 11K | 9K | 11K | 5K | 5K | 25K | 306K | -187K | -93K | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 59.17M | 59.12M | 59.11M | 59.02M | 47.37M | 42.42M | 42.4M | 27.58M | 23.62M | 23.3M | 23.29M | 23.26M | 23.22M | 12.13M | 23.11M | 1.05M | 22.82M |
Shares Outstanding (Diluted) | 59.17M | 59.12M | 59.11M | 59.02M | 47.37M | 42.42M | 42.4M | 27.58M | 23.62M | 23.3M | 23.29M | 23.26M | 23.22M | 12.13M | 23.11M | 1.05M | 22.82M |
EPS (Basic) | -0.24 | -0.18 | -0.22 | -0.18 | -0.23 | -0.19 | -0.25 | -0.37 | -0.72 | -0.82 | -1.68 | -0.85 | -0.74 | -0.79 | -0.53 | -4.84 | -0.22 |
EPS (Diluted) | -0.24 | -0.18 | -0.22 | -0.18 | -0.23 | -0.19 | -0.25 | -0.37 | -0.72 | -0.82 | -1.68 | -0.85 | -0.74 | -0.79 | -0.53 | -4.84 | -0.22 |
EBITDA | -14.22M | -9.46M | -13.22M | -10.96M | -9.86M | -7.94M | -10.91M | -9.82M | -11.63M | -18.54M | -38.52M | -20.11M | -17.36M | -9.62M | -12.27M | -5.05M | -5.08M |
EBIT | n/a | -9.47M | -13.23M | -10.96M | -9.87M | -9.08M | -10.92M | -9.83M | -11.64M | -18.54M | -38.53M | -20.11M | -17.37M | -9.62M | -12.28M | -5.06M | -5.09M |
Depreciation & Amortization | n/a | 5K | 5K | 4K | 10K | 10K | 9K | 10K | 10K | 10K | 8K | 5K | 4K | 5K | 3K | 6K | 4K |